Recombinant Streptokinase

About Epygen Biotech

Epygen Biotech is a private, US-based biopharmaceutical company founded in 2019, specializing in the development and manufacturing of biosimilar and novel therapeutic proteins. Its pipeline includes programs in oncology (Pegfilgrastim, Bevacizumab), cardiovascular (Recombinant Streptokinase), hormones (Teriparatide), and vaccines (SARS-CoV-2), supported by in-house CDMO capabilities. The company's strategy centers on leveraging its recombinant protein technology platform to produce high-quality, affordable biologics for global markets, though it appears to be in a pre-revenue or early development stage.

Therapeutic Areas